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Leveraging a Public-Private-Academic Collaborative
Partnership to Confront Challenges in the
COVID-19 Pandemic
James Denvir, PhD1

ABSTRACT
Like all viruses, the SARS-CoV-2 virus mutates over time, creating new viral variants
that have the potential to transmit more rapidly, cause more severe disease, or avoid
treatment and prevention strategies. A critical component of the public health response
to COVID-19 is identifying and tracking the emergenc of SARS-CoV-2 variants. In West
Virginia, this effort is coordinated via a public-private-academic collaboration.
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Following the initial outbreak of COVID-19 in December 2019 and its spread to the United States in the
following two months, initial efforts were focused on
quickly and accurately diagnosing the disease. The
predominant form of test developed uses reverse
real-time reverse-transcriptase polymerase chain
reaction (rRT-PCR) on samples, typically obtained via
a nasopharyngeal swab. rRT-PCR is a common and
relatively simple laboratory procedure and in the
United States a number of commercial laboratories
who were already equipped to perform this test
quickly mobilized to provide large-capacity testing
nationwide.
As with all viruses, the RNA replication of SARS-CoV-2,
the virus causing COVID-19, is imperfect. Because of
this, new genetic variants of the virus emerge over
time. Some of these genetic variants, particularly
those involving specific mutations in the S gene,
which translates to the spike protein, confer evolutionary advantages1. These advantages may include
increased transmissibility and/or the potential for
more severe disease and as such pose an increased
public health risk. There is the potential for genetic
variation in the virus to cause decreased susceptibility
to treatment or vaccination. At the time of writing,
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the Centers for Disease Control (CDC) has classified
five specific variants as “variants of concern”. Using the
PANGOLIN nomenclature, these variants of concern
are B.1.1.72, first discovered in the United Kingdom
in October 2020, B.1.3513, first seen in South Africa in
December 2020, P.14, first observed in Japan in January 2021 in patients who had recently traveled from
Brazil and later observed in samples from Brazil which
were collected in December 2020, and B.1.427 and
B.1.4295, which were both first observed in California
in July 2020. The CDC has identified three further
variants which are classified as “variants of interest”.
The “variants of high consequence” category, which is
intended for the variants most threatening to public
health, currently has no variants assigned to it.
Identifying and tracking the prevalence of genetic
variants of SARS-CoV-2 has become a public health
priority. By identifying SARS-CoV-2 variants, epidemiologists can identify which variants have increased
transmissibility as well as detect occurrences of
known variants of concern. This in turn allows them
to rapidly perform contact tracing and, if necessary,
implement public health policies to mitigate the
spread of more transmissible forms of the virus.
Determining the variant of a particular viral sample
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requires sequencing all 29,903 nucleotides in the viral
genome. By contrast to diagnostics by rRT-PCR, this
requires highly specialized, high-throughput sequencing technology and technical expertise both in
laboratory processes and in data analysis.
In December 2020, the West Virginia “Coronavirus
Czar” and Dean of the School of Medicine at West
Virginia University, Dr. Clay Marsh, asked Dr. Laura
Gibson, senior vice president for research at the
WVU Health Sciences Center, to assemble a team to
perform viral sequencing from positive SARS-CoV-2
samples from across the state. Dr. Gibson leveraged
the genomics core facilities at WVU and Marshall
University, the bioinformatics core facility at Marshall
University, the state epidemiology laboratory at the
WV Department of Health and Human Resources
(DHHR), and WVU and commercial testing facilities
across the state in order to develop a pipeline to
identify SARS-CoV-2 variants. The WVU and Marshall
University components of this team have a record of
close collaboration spanning over a decade. The development of this pipeline requires complex logistics
in moving samples from testing labs to sequencing

labs and maintaining records of the origin of each
sample while protecting private health information.
Sequencing laboratory protocols had to be tested
and optimized. A data analysis pipeline had to be developed, and high-performance computing resources
were required in order to run it. Information management protocols for dissemination of occurrences of
variants of concern to the DHHR and the state governor’s coronavirus task force had to be implemented.
The first sequencing run was completed on February
19th 2021 at the WVU genomics core facility and
resulted in the detection of three samples with the
B.1.1.7 variant. At the time of writing, eight sequencing runs have been completed, identifying the variant
of 1,686 individual samples. These samples are drawn
both from “surveillance” of predominantly asymptomatic subjects and clinical samples from symptomatic patients. The resulting data set can be used, for
example, to visualize the change of distribution of the
different variants across time (Figure 1).
All five variants of concern have been detected in the
state. The last to be detected was P.1 on April 16th
2021; contact tracing was initiated and the public

FIGURE 1. Change in distribution of selected SARS-CoV-2 variants in West Virginia among sequenced clinical (left
panel) and surveillance (middle panel) samples, showing the emergence and eventual dominance of B.1.1.7 over the
B.1.2 variant. For comparison, the distribution across the USA over the same time period is shown (right panel), using
data downloaded from NCBI GenBank.
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was informed within hours of the completion of
sequencing in the laboratory. Sequences from these
samples, along with metadata, have been submitted to the Global Initiative on Sharing All Influenza
Data (GISAID) in order to contribute to global epidemiology and other data analyses.
The rapid development of this pipeline was only
possible by leveraging specific technical expertise,
dedicated specialized equipment, and existing
collaborations that are almost uniquely present in
academic environments. The academic core facilities
that provide this functionality are supported in part
by investments in the form of grant funding from
the National Institute for General Medical Sciences.
The academic entities collaborate with corporate
laboratories that provide the positive samples and
the DHHR who enact the public health policies in
response to the scientific findings.
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This one-of-a-kind, public-private-academic partnership demonstrates the value of public investment in academic institutions and how the ongoing
support of science can contribute to the well-being
of society, particularly in times of a public health
emergency.
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